Abstract
Cyclocreatine, an analog of creatine, is an efficient substrate for creatine kinase, but its phosphorylated form is a poor phosphate donor in comparison with creatine phosphate. Cyclocreatine was not very cytotoxic upon 24 h of exposure of human SW2 small-cell lung cancer cells to concentrations of up to 5 mM. However, combinations of cyclocreatine (0.5 mM, 24 h) with each of four antitumor alkylating agents, cis-diamminedichloroplatinum(II), melphalan, 4-hydroperoxycyclophosphamide, and carmustine, resulted in additive to greater-than-additive cytotoxicity toward exponentially growing SW2 cells. The greatest levels of synergy were seen at higher concentrations of 4-hydroperoxycyclophosphamide and carmustine as determined by isobologram analysis. In vivo cyclocreatine (0.5 or 1 g/kg) was more effective if given i.v. rather than i.p. The longest tumor-growth delays, up to 10 days, were produced by extended regimens of cyclocreatine. Cyclocreatine was an effective addition to therapy with standard anticancer agents including cis-diamminedichloroplatinum(II), cyclophosphamide, Adriamycin, or 5-fluorouracil. No additional toxicity was observed when 10 days of cyclocreatine treatment was given with full standard-dose regimens of each drug. The resultant increases in tumor-growth delay were 1.7- to 2.4-fold as compared with those obtained for each of the drugs alone. These results indicate that cyclocreatine may be an effective single agent and an effective addition to combination chemotherapy regimens.
Similar content being viewed by others
References
Annesley TM, Walker JB (1977) Cyclocreatine phosphate as a substitute for creatine phosphate in vertebrate tissues. Energetic considerations. Biochem Biophys Res Commun 74: 185–190
Becker S, Schneider F (1989) Investigations on the function of creatine kinase in Ehrlich ascites tumor cells. Biol Chem Hoppe Seyler 370: 357–364
Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 28: 1–18.
Carney DN, Zweig MH, Ihde DC, Cohen MH, Makuch RW, Gazdar AF (1984) Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Res 44: 5399–5403
Chida K, Kasahara K, Tsunenaga M, Kohno Y, Yamada S, Ohmi S, Kuroki T (1990) Purification and identification of creatine phosphokinase B as a substrate of protein kinase C in mouse skin in vivo. Biochem Biophys Res Commun 173: 351–357
Deen DF, Williams ME (1977) Isobologram analysis of x-ray-BCNU interactions in vitro. Radiat Res 79: 483–491
Francis J, Bernai SD, Gazdar AF, Thompson R, Baylin S (1980) L-Dopa decarboxylase activity (DDC): a distinguished biomarker for the growth of small cell lung cancer (SCCL) in tissue culture. Proc Am Assoc Cancer Res 21: 52
Francis K, Thompson R, Bernai SD, Luk G, Baylin SA (1983) Effects of dibutyral adenosine 3′,5′-monophosphate on growth of cultured human small cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase. Cancer Res 43: 639–645
Futscher BW, Dalton WS (1993) P-glycoprotein mediated multidrug resistance. In: Teicher BA (ed) Drug resistance in oncology. Marcel Dekker, New York, pp 461–479
Kaddurah-Daouk R, Lillie JW, Daouk GH, Green MR, Kingston R, Schimmel P (1990) Induction of a cellular enzyme for energy metabolism by transforming domains of adenovirus Ela. Mol Cell Biol 10: 1476–1483
Lillie JW, O’Keefe M, Valinski H, Hamlin HA Jr, Varban ML, Kaddurah-Daouk R (1993) Cyclocreatine (l-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors. Cancer Res 53: 3172–3178
Mahadevan LC, Whatley SA, Leung TKC, Lim L (1984) The brain isoform of a key ATP-regulating enzyme, creatine kinase, is a phosphoprotein. Biochemistry 222: 139–144
Miller EE, Evans AE, Cohn M (1993) Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad Sci USA 90: 3304–3308
Ohira Y, Ishine S, Inoue N, Yunoki K (1991) Reduced growth of Ehrlich ascites tumor cells in creatine depleted mice fed β-guanidinopropionic acid. Biochim Biophys Acta 1097: 117–122
Quest AFG, Soldati T, Henner W, Perriard JC, Eppenberger HM, Wallimann T (1990) Phosphorylation of chicken braintype creatine kinase affects a physiologically important kinetic parameter and gives rise to protein microheterogeneity in vivo. FEBS Lett 269: 457–464
Segaloff A (1966) Hormones and breast cancer. Recent Prog Horm Res 22: 351–374
Steel GG, Peckman MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Oncol Biol Phys 15: 85–91
Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E III (1986) Alkylating agents: in vitro studies of cross-resistance patterns. Cancer Res 46: 4379–4383
Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E III (1987) Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 47: 388–393
Teicher BA, Holden SA, Cucchi CA, Cathcart KNS, Korbut TT, Flatow JL, Frei E III (1988) Combination of N,N′,N″- triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 48: 94–100
Teicher BA, Herman TS, Holden SA, Eder JP (1991) Chemotherapeutic potentiation through interaction at the level of DNA. In: Chow T-C, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic Press, New York, pp 541–584
Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E III (1991) Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47: 252–260
Walker JB (1979) Creatine: biosynthesis, regulation, and function. Adv Enzymol 50: 177–241
Walliman T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM (1992) Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the ‘phosphocreatine circuit’ for cellular energy homeostasis. Biochem J 281: 21–40
Warburg O (1956) On respiratory impairment in cancer cells. Science 124: 269
Weintraub H, Hauschka S, Tapscott SJ (1991) The MCK enhancer contains a p53 responsive element. Proc Natl Acad Sci USA 88: 4570–4571
Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ (1992) Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6: 1143–1152.
Author information
Authors and Affiliations
Additional information
This work was supported by NIH grant RO1-50174 and a grant from AMIRA, Inc., Cambridge, Massachusetts
Rights and permissions
About this article
Cite this article
Teicher, B.A., Menon, K., Northey, D. et al. Cyclocreatine in cancer chemotherapy. Cancer Chemother. Pharmacol. 35, 411–416 (1995). https://doi.org/10.1007/s002800050255
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002800050255